Package Leaflet: Information for the User
Apixaban Macleods 5 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
This medicine contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent the formation of blood clots by blocking Factor Xa, an important component of blood clotting.
Apixaban is used in adults:
Apixaban is used in children from 28 days to less than 18 years of age to treat blood clots and to prevent these blood clots from recurring in the veins and blood vessels of the lungs.
For the recommended dose suitable for body weight, see section 3.
Do not take apixaban if:
Warnings and precautions
Tell your doctor, pharmacist, or nurse before taking this medicine if you have any of these conditions:
Be careful with apixaban
If you need surgery or a procedure that may cause bleeding, your doctor will tell you to temporarily stop taking this medicine for a while. If you are not sure if a procedure may cause bleeding, consult your doctor.
Children and adolescents
This medicine is not recommended for use in children and adolescents with a body weight below 35 kg.
Other medicines and Apixaban Macleods
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use other medicines.
Some medicines may increase the effects of apixaban and some medicines may decrease its effects. Your doctor will decide if you should be treated with apixaban if you are taking these medicines and if you should be kept under closer observation.
The following medicines may increase the effects of apixaban and increase the possibility of unwanted bleeding:
The following medicines may reduce the ability of apixaban to prevent blood clot formation:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor, pharmacist, or nurse before using this medicine.
The effects of apixaban on pregnancy and the fetus are unknown. You should not take this medicine if you are pregnant. Tell your doctor, pharmacist, or nurse immediatelyif you become pregnant while taking this medicine.
It is unknown whether apixaban is excreted in human milk. Ask your doctor, pharmacist, or nurse before taking this medicine during breastfeeding. They will tell you whether to interrupt breastfeeding or whether to stop or not start taking this medicine.
Driving and using machines
Apixaban has no influence on the ability to drive or use machines.
Apixaban Macleods contains lactose (a type of sugar) and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are in doubt, consult your doctor, pharmacist, or nurse again.
Dosage
Take the tablet with water. Apixaban can be taken with or without food.
Try to take the tablets at the same time each day to achieve a better effect of the treatment.
If you have difficulty swallowing the tablet whole, talk to your doctor about other possible ways to take apixaban. The tablet can be crushed and mixed with water, 5% glucose in water, apple juice, or apple puree, immediately before taking it.
Instructions for crushing:
If necessary, your doctor may also administer the crushed apixaban tablet mixed in 60 ml of water or 5% glucose in water through a nasogastric tube.
Take apixaban according to the following recommendations:
To prevent the formation of a blood clot in the heart of patients with an irregular heartbeat and at least one additional risk factor.
The recommended dose of apixaban is one apixaban 5 mgtablet twice a day.
The recommended dose is one apixaban 2.5 mgtablet twice a day if:
The recommended dose is one tablet twice a day, for example, take one tablet in the morning and one in the evening. Your doctor will tell you how long you should continue the treatment.
To treat blood clots in the veins of the legs and in the blood vessels of the lungs
The recommended dose is twoapixaban 5 mgtablets twice a day for the first 7 days, for example, two tablets in the morning and two tablets in the evening.
After 7 days, the recommended dose is oneapixaban 5 mgtablet twice a day, for example, one tablet in the morning and one tablet in the evening.
To prevent blood clots from recurring after 6 months of treatment
The recommended dose is one apixaban 2.5 mgtablet twice a day, for example, one tablet in the morning and one tablet in the evening.
Your doctor will tell you how long you should continue the treatment.
Use in children and adolescents
For the treatment of blood clots and to prevent these blood clots from recurring in the veins and blood vessels of the lungs.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are in doubt, consult your doctor, pharmacist, or nurse.
Try to take or administer the dose at the same time each day to achieve a better effect of the treatment.
The dose of apixaban depends on body weight and will be calculated by your doctor.
The recommended dose for children and adolescents with a weight of at least 35 kg is twoapixaban 5 mgtablets twice a day for the first 7 days, for example, two tablets in the morning and two tablets in the evening.
After 7 days, the recommended dose is oneapixaban 5 mgtablet twice a day, for example, one tablet in the morning and one tablet in the evening.
For parents and caregivers: observe the child to ensure they take the complete dose.
It is important to respect scheduled visits to the doctor, as it may be necessary to adjust the dose based on changes in weight.
Your doctor may change your anticoagulant treatment as follows:
Stop taking apixaban. Start treatment with other anticoagulant medicines (e.g., heparin) at the time you would take the next apixaban tablet.
Stop taking other anticoagulant medicines. Start treatment with apixaban at the time you would take the next dose of the other anticoagulant medicine, and then continue as usual.
Stop taking the medicine that contains a vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to start taking apixaban.
If your doctor tells you to start taking a medicine that contains a vitamin K antagonist, continue taking apixaban for at least 2 days after your first dose of the medicine that contains a vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to stop taking apixaban.
Patients undergoing cardioversion
If your heartbeat needs to be restored through a process called cardioversion, take this medicine at the times your doctor indicates to prevent blood clots in the blood vessels of the brain and other blood vessels of the body.
If you take more apixaban than you should
Tell your doctor immediatelyif you have taken a dose higher than the prescribed dose of this medicine. Take the medicine pack to your doctor, even if there are no tablets left.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested
If you take more apixaban than the recommended dose, you may increase the risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that can reverse anti-factor Xa activity may be necessary.
If you forget to take apixaban
If you are in doubt about what to do or if you forget to take more than one dose,ask your doctor, pharmacist, or nurse.
If you stop taking apixaban
Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot may be greater if you stop the treatment too soon.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. The most frequent adverse effect of this medicine is bleeding, which can put the patient's life at risk and requires immediate medical attention.
The following adverse effects have been reported when taking apixaban to prevent the formation of blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Unknown Frequency (cannot be estimated from available data)
The following adverse effects have been reported when taking apixaban to treat or prevent blood clots from recurring in the veins of the legs and blood vessels of the lungs.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Unknown Frequency (cannot be estimated from available data)
Additional Adverse Effects in Children and Adolescents
Inform the child's doctor immediatelyif you observe any of these symptoms:
In general, the adverse effects observed in children and adolescents treated with Apixaban Macleods were similar to those observed in adults and mainly of mild to moderate intensity. The most frequent adverse effects in children and adolescents were nosebleeds and abnormal vaginal bleeding.
Very Frequent Adverse Effects (may affect more than 1 in 10 people)
Frequent Adverse Effects (may affect up to 1 in 10 people)
Unknown Frequency (cannot be estimated from available data)
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and on each blister, after EXP. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the pharmacy's SIGRE Point. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Apixaban Macleods
Appearance of the Product and Package Contents
Round, biconvex, film-coated tablets, pink in color, and engraved with "F 52" on one side, and smooth on the other.
This medicine is available in:
Not all package sizes may be marketed.
Patient Information Card: Information Management
Inside the packaging of this medicine, along with the leaflet, you will find a patient information card or your doctor may give you a similar card.
This patient information card includes useful information for you and will inform other doctors that you are being treated with apixaban. You must keep this card with you at all times.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Macleods Pharma España S.L.U.
World Trade Center Barcelona
Moll de Barcelona, s/n,
08039 Barcelona,
Spain
Manufacturer
Synoptis Industrial Sp. z o.o.
Rabowicka 15, Swarzedz, 62-020,
Poland
This medicine is authorized in the Member States of the European Economic Areawith the following names:
Germany | Apixaban Macleods 5 mg Filmtabletten |
Spain | Apixabán Macleods 5 mg comprimidos recubiertos con película EFG |
Netherlands | Apixaban Macleods 5 mg filmomhulde tabletten |
Date of the Last Revision of thisLeaflet:July 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).